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A panel of 52 murine monoclonal antibodies was found to
recognize antigenic determinants that had been conserved among
all major genetic subgroups of the H5N1 avian influenza virus
prevalent since 1997. We screened a phage display library for
peptides recognized by one such antibody (8H5). We analysed
the specificity of 8H5 for reactive peptides presented as fusion
proteins of HBc (hepatitis B core protein) and HEV (hepatitis
E virus) structural protein, p239. This was then related to
the specificity of the native HA (haemagglutinin) molecule by
virtue of the capacity of fusion proteins to compete for 8H5
binding with different strains of H5N1 virus and the reactivity
of antisera generated against fusion proteins to bind native HA
molecules, and to inhibit haemagglutination and arrest infection
by the virus. Nine reactive peptides of different amino acid
sequences were identified, six of which were also reactive
with the antibody in association with HBc and four were in
association with p239. Binding occurred with the dimeric form
of the four p239-fusion proteins and one of the HBc-fusion
proteins, but not with the monomeric form. The HBc-fusion pro-
teins blocked 8H5 binding with four strains of H5N1 influenza
virus. Mouse antisera generated against fusion proteins bound
to HA molecules, but did not inhibit haemagglutination or
arrest H5N1 infection. Our findings indicate that 8H5 recognizes
discontinuous sites presented by secondary and possibly higher
structural orders of the peptides in spatially favourable positions
for binding with the antibody, and that the peptides partially mimic
the native 8H5 epitopes on the H5N1 virus.
Key words: anti-H5 monoclonal antibody, H5N1 avian influenza
virus, haemagglutination, hepatitis virus, influenza, peptide
mimic.
INTRODUCTION
The H5N1 avian influenza virus normally circulates among
aquatic birds, but is highly pathogenic for territorial birds
and causes fatal infections in humans. H5N1 influenza viruses
began to spread from late 2003, causing disease outbreaks
in China, Japan, South Korea, Thailand, Vietnam, Indonesia,
Cambodia, Malaysia and Laos. This resulted in extensive loss
of chickens, ducks and geese [1]. Recently, H5N1 infection of
humans has again been detected in many countries around the
world. Of 346 confirmed cases, 213 were fatal (http://www.who.
int/csr/disease/avian_influenza/country/en/). Although there is no
evidence for transmission among humans to date, the virus has
evolved rapidly, raising the threat that the virus may become
adapted to humans, causing an influenza pandemic.
Vaccination is considered the most effective preventive measure
to control influenza. Various approaches have been used to
generate an H5N1 vaccine for human immunization [3–9], but
efficacy of the vaccine against the pandemic strain is uncertain.
Vaccines based on M2e (matrix protein 2 ectodomain) and NA
(neuraminidase) might be more cross-reactive than those based
on variable HA (haemagglutinin) [10–12].
We have generated over 200 mAbs (monoclonal antibodies) by
successively immunizing mice with different genetic subgroups
of the H5N1 virus. In line with studies using conventional ferret
antisera highlighting antigenic diversity of the virus population
[13,14], over 70% of these antibodies were found to exhibit a
distinct and restricted reactivity spectrum against different virus
strains, but, unlike conventionally produced antisera, a substantial
proportion of mAbs exhibited broad reactivity against the virus,
presumably because of repeatedly boosting the antibody
response of the animals to common antigenic determinants
shared by different immunizing virus strains [15]. We showed
further that 52 of these antibodies were capable of inhibiting
haemagglutination mediated by 42 strains belonging to ten major
genetic groups of H5N1 virus prevalent since 1997, exhibiting
broad-spectrum neutralizing activity against these viruses, and
one of these antibodies was tested and found to protect mice
against these viruses even at late stages of infection [16]. These
findings suggest that these broad-spectrum anti-H5N1 antibodies
may recognize conserved antigenic determinants associating
with neutralization sites of H5N1 virus, and, as such, these
conserved determinants are potential targets for broad-spectrum
intervention of H5N1 avian influenza.
The technology of epitope-based vaccine has evolved rapidly
in the recent years (see [17] for a review). The immune responses
to pathogens induced by native epitope and mimotope have been
applied in the research of many diseases, including tumours, HIV
and HCV (hepatitis C virus) [18–22]. In order to elucidate the
conserved site in the HA molecules of H5N1 virus, we screened a
phage display library of combinatorial 12-mer peptides for peptide
reactive with a pan-H5 mAb, 8H5. The antibody has been shown to
be reactive against all of the major genetic groups of H5N1 viruses
prevalent since 1997, and it was found to neutralize different
Abbreviations used: gp120, glycoprotein 120; HA, haemagglutinin; HBc, hepatitis B core protein; HEV, hepatitis E virus; HI, haemagglutination inhibition;
HRP, horseradish peroxidase; LB, Luria–Bertani; mAb, monoclonal antibody.
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Table 1 Murine mAbs
Six murine mAbs were used in the present study. Five were generated against the H5N1 influenza
virus [15,16] and one was generated against HEV [23], as indicated.
mAb Ig subtype Specificity
8H5 IgG2a H5N1 influenza virus
4D1 IgG1 H5N1 influenza virus
8G9 IgG2b H5N1 influenza virus
10F7 IgM H5N1 influenza virus
2F2 IgG1 H5N1 influenza virus
8C11 IgG1 HEV
H5N1 virus in a cell-based neutralization assay [16]. We showed
that some of these 8H5-reactive peptides are antigenically related
to native HA molecules of the H5N1 virus.
MATERIALS AND METHODS
Virus strains
The H5N1 influenza virus strains, Chicken/Hong Kong/YU22/
2002 (YU22), Rosybilled Pochard/Hong Kong/821/2002
(HK821), Chicken/Jiangxi/6151/ 2003 (6151) and Indonesia/2A/
2004 (2A), were provided by State Key Laboratories of Emerging
Infectious Diseases, Department of Microbiology, University
of Hong Kong. The Sf21 insect cell line was purchased from
Invitrogen.
Monoclonal antibodies
We used six murine mAbs in the present study. Five were
generated against the H5N1 influenza virus and one was
generated against HEV (hepatitis E virus) (Table 1). As described
previously [15], the H5N1-specific antibodies were generated
by successively immunizing Balb/c mice with five strains of
H5N1 avian influenza virus representing different major genetic
subgroups of the virus prevalent since 2002 and found to have
caused human infection, and all four of the antibodies, including
8H5, exhibit broad but distinct H5 specificity [16]. The HEV-
specific antibody was generated against a recombinant structural
protein of HEV as described by Zhang et al. [23]. The antibodies
were produced as ascetic fluids, purified by ammonium sulfate
precipitation followed by DE52 column chromatography, and
stored in aliquots at −20 ◦C until use. Immunoglobulin subtypes
of the antibodies were determined using mAb-isotyping reagent
(BD Biosciences).
Screening of phage library for 8H5-reactive peptides
A combinational 12-mer peptide phage display library (New
England Biolabs) was used to screen for peptides that bind to
8H5 mAb, according to the manufacturer’s instructions. Briefly,
2 × 1011 phage particles and 300 ng of mAb were mixed and
incubated at room temperature (27 ◦C) for 20 min. Then, 50 μl
of Protein A-conjugated magnetic beads (GE Healthcare) was
added to the mixture, and the beads were washed three times
to remove unbound phage. 8H5-bound phage was eluted and
propagated in Escherichia coli cells (ER2738) cultured in LB
(Luria–Bertani) medium. After three rounds of panning, bound
phage was eluted and cloned by mixing serially diluted aliquots
of phage with E. coli and plating the mixtures on LB/IPTG
(isopropyl β-D-thiogalactoside)/X-Gal (5-bromo-4-chloroindol-
3-yl β-D-galactopyranoside) plates. Resulting plaques consisting
of cloned phage were randomly picked and propagated and tested
by ELISA for binding with 8H5 and control antibodies. Inserts
encoding the peptides were isolated from 8H5-reactive phage
using the phage ssDNA (single-stranded DNA) isolation reagent
kit (Omega) and sequenced by Bioasia.
Fusion proteins carrying 8H5-reactive peptides
The sequences encoding the 12-mers were linked to the C-ter-
minus of the gene encoding the HEV structural protein p239
[24] or inserted to positions 79 and 80 of the residue 1–149
fragment of HBc (hepatitis B core protein) [25,26]. The resulting
chimaeric constructs were inserted to the pT0-T7 expression
vector and expressed in E. coli as described previously [23].
p239-fusion proteins were recovered in the pellet of cell lysates,
treated with 2% (v/v) Triton X-100 at 37 ◦C for 30 min and then
dissolved in 8 M urea. The proteins were renatured by dialysis
against PBS (pH 7.45) at room temperature. The HBc-fusion
protein was recovered from the supernatants of cell lysates. The
fusion proteins were precipitated at 20%-satd. ammonium sulfate,
resuspended in carbonate/bicarbonate buffer containing 5 % (w/v)
2-mercaptoethanol, by shaking at 37 ◦C for 30 min, and dialysed in
phosphate buffer (pH 7.4). The resulting purified fusion proteins
were kept at 4 ◦C until use.
Fusion proteins were examined by negative-stain electron
microscopy. Protein samples were applied to a carbon-coated grid,
and excess fluid was removed. Protein samples were stained with
2% (w/v) uranyl acetate and examined using an F30 transmission
electron microscope (Phillips) operating at 200 kV.
Immunoassays
ELISA for phage particles
Approx. 109 plaque-purified phages were added to microplates
coated previously with 10 μg/ml 8H5 mAb, and control plates
were coated with the same concentrations of three different
antibodies (4D1, 10F7 and 8C11). After incubation at 37 ◦C for
1 h, plates were washed three times and incubated further at
37 ◦C for 30 min with a M13-phage-specific HRP (horseradish
peroxidase)-conjugated antibody (GE Healthcare) at 1:5000
dilution. The plates were allowed to react with TMB (3,3′,5,5′-
tetramethylbenzidine) liquid substrate system and read on a
microplate reader.
ELISA test for fusion proteins
Purified fusion proteins (10 μg/ml in phosphate buffer, pH 7.4)
were coated on to 96-well microplates at 37 ◦C for 2 h. The
plates were blocked with ED buffer [PBS, pH 7.4, containing 2 %
gelatin, 0.5% casein and 0.1% ProClin 300 (Sigma–Aldrich)],
washed and incubated with 4 μg/ml 8H5 or control antibodies at
37 ◦C for 1 h. Then, 100 μl of goat anti-(mouse IgG) conjugated
to HRP (1:10000 dilution) was added to each well and incubated
at 37 ◦C for 30 min. Colour development was as described above.
Competitive ELISA test
The 8H5 mAb at a concentration of 10 μg/ml in phosphate buffer
(pH 8.0) was coated on to 96-well plates at 37 ◦C for 2 h. The plates
were washed once, followed by blocking with ED buffer. Then, the
purified fusion proteins (10 μg/ml) and H5 avian influenza virus
(4HA of YU22 or HK821, 8HA of 6151 or 2HA of 2A) were
added to the wells together and incubated at 37 ◦C for 30 min.
HBc antigen protein was used as a negative control. 2F2–HRP
(1:500 dilution) against H5 avian influenza virus was used as the
secondary antibody.
Western blotting
The purified fusion proteins were resolved by SDS/PAGE
(12% polyacrylamide gel), transferred on to a nitrocellulose
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membrane, and reacted with 8H5 mAb at room temperature
for 1 h. The membrane was then treated with goat anti-(mouse
IgG) conjugated to HRP (1:10000 dilution) and then developed
with AEC (3-amine-9-ethylcarbazole) (single solution; Zymed
Laboratories) to reveal protein bands.
Antisera against HBc-fusion proteins
The purified chimaeric HBc proteins were emulsified with an
equal volume of complete Freund’s adjuvant and primed Balb/c
mice were injected subcutaneously at multiple sites at the dose
of 100 μg of protein per mouse. A booster immunization using
an incomplete Freund’s adjuvant was given every other week.
Blood was collected from the mice’s eyes, and the antiserum was
separated from clotted blood and stored at −4 ◦C for future use.
All animal experiments were conducted in compliance with the
humane and ethical treatment of experimental animal rules and
regulations required by the Chinese government.
Flow cytometry
FACS analysis was carried out to detect the reaction of mouse
antiserum with HA of YU22 virus that was expressed on Sf21
cells, using a FACScan flow cytometer (Beckman Coulter) with
the FL1 detector channel. The data were analysed with Expo32
ADC Analysis software (Beckman Coulter).
The Sf21 cells were infected by recombinant baculovirus
containing the HA gene of YU22 virus, incubated for 36 h, and
were compared with negative control Sf21 cells without HA gene
infection. Up to 106 cells/sample were collected, washed with PBS
and blocked with goat serum for 30 min. The cell suspensions
were then incubated with mouse serum for 1 h. After washing,
the cell suspensions were incubated with a FITC-conjugated goat
anti-(mouse Fc) secondary antibody (Sigma–Aldrich) for 30 min
and washed again before FACS analysis. All procedures were
performed at room temperature. Results are presented as peak
graphs and the percentage of positive cells.
HI (haemagglutination inhibition) test
The HI test was performed to assess the reactivity of antiserum
against H5N1 isolates, using the method described in [27].
All polyclonal antisera were treated with a receptor-destroying
enzyme (Denka Seiken) before testing. The HI test was started
at a 1:40 dilution for polyclonal antiserum and 1:100 dilution for
mAb and adsorbed with a 0.5% suspension of chick red blood
cells.
RESULTS
Identification of 8H5-reactive 12-mer peptides
We screened for 8H5-binding peptides by panning a phage display
library of combinational 12-mer peptides with the antibody. A
total of 190 plaques were picked from the plates, propagated
individually and tested in triplicate by ELISA for binding with
8H5 and three control antibodies, two of which (4D1 and 10F7)
were other pan-H5 mAbs and one (8C11) is an HEV-specific
mAb (Figure 1). Specific 8H5 binding is indicated when mean
8H5 binding exceeds that concurrently obtained with the control
antibodies at least 3-fold. Table 2 showed that 69 (36%) of
190 clones of phage (plaques) tested were 8H5-reactive. DNA
sequencing of inserts from these phage isolates distinguished nine
reactive peptides of different amino acid sequences. This suggests
that the antibody recognizes discontinuous amino acid residues of
these peptides. It was noted that four amino acid residues, namely
threonine, leucine, threonine and leucine, were preserved in the
Table 2 Identification of 8H5-reactive peptides isolated from the phage
display library
A total of 190 randomly picked clones of screened phage were individually tested by ELISA
for 8H5 binding as described in Figure 1. DNA sequences of inserts from 69 clones of phage
that were found to be reactive distinguished nine different peptides. Note that the four amino
acid residues underlined, namely threonine, leucine, threonine and leucine, were preserved in
positions 2, 4, 5 and 9 of six of these peptides, which together accounted for 63 of the 69
8H5-reactive phage clones.










Figure 1 Identification of 8H5-reactive phagotopes
A combinatorial 12-mer phage display library was screened for 8H5-reactive phagotopes.
Screened phage was cloned and tested by ELISA for binding with 8H5 and three control
antibodies, consisting of two other H5-specific antibodies (4D1 and 10F7) and an HEV-
specific antibody (8C11). Assays were carried out in triplicate and results are means +− S.D.
Phage was considered to be 8H5-reactive when mean absorbance values obtained with this
antibody exceeded at least 3-fold that of the control antibodies.
same positions 2, 4, 5 and 9 respectively in amino acid sequences
of six of these peptides, and that the same peptides together
accounted for 63 (95%) of 69 clones of 8H5-reactive phages
isolated, including the most frequently isolated carrying peptides
124 and 125.
8H5 binding by 12-mer peptides associated with carrier proteins
Fusion proteins of HBc and p239 carrying different 8H5-reactive
peptides were produced as described in the Materials and methods
section. Preliminary studies showed that the p239-fusion proteins
occurred as 23 nm particles and HBc-fusion proteins as 30 nm
particles, and both were dissociated mainly into dimeric and
monomeric forms after they had been subjected to SDS/PAGE
(results not shown). The fusion proteins were tested for 8H5 bind-
ing by ELISA conducted under non-denaturing conditions and by
Western blotting, where the fusion proteins were first subjected to
SDS/PAGE. ELISA conducted under non-denaturing conditions
showed that four p239-fusion proteins carrying peptides 122,
123, 125 and 129, and six HBc-fusion proteins carrying these
and peptides 124 and 128 were reactive with 8H5 (Figure 2). In
c© The Authors Journal compilation c© 2009 Biochemical Society
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Figure 2 Binding of 8H5 and control antibodies to p239- and HBc-fusion
proteins
Fusion proteins of p239 and HBc antigen carrying the different peptides, together with the
parental p239 and HBc antigen, were tested by ELISA for binding with 8H5 and other pan-H5
mAbs. Assays were carried out in triplicate, and results are shown as means +− S.D. absorbance.
Western blotting (Figure 3), p239-fusion proteins were resolved
by SDS/PAGE mainly as dimeric and monomeric forms, with the
dimeric form being dominant (top-left-hand panel). HBc-fusion
proteins were likewise resolved as dimeric and monomeric forms,
with the latter being the more abundant (bottom-left-hand panel).
8H5 reactivity was detected in association with the dimeric form
of three p239-fusion proteins (top-right-hand panel) and one of
the HBc-fusion proteins (bottom-right-hand panel). It was noted
that the monomeric forms of either types of fusion proteins were
not reactive with the antibody.
As summarized in Table 3, nine 8H5 reactive peptides were
identified from the phage display library. Six of these peptides
were also reactive when presented as HBc-fusion proteins and
four were reactive as p239-fusion proteins. The reactivity was
detected in association with native and most probably particulate
form of the fusion proteins by ELISA under non-denaturing
conditions. After being dissociated into dimeric and monomeric
forms during Western blotting, the reactivity was located to the
dimeric form of three p239-fusion proteins and one HBc-fusion
protein, whereas the monomeric form of either fusion proteins did
not exhibit detectable binding with the antibody. These findings
infer that recognition by 8H5 is based on folding and possibly
higher structural orders of these peptides.
Mimicry of native 8H5-binding sites by 12-mer peptides
The HBc-fusion proteins were characterized further according to
their capacity to compete with avian influenza viruses for binding
with 8H5 (Figure 4). In these experiments, 10 μg/ml of the fusion
proteins was mixed with different strains of H5N1 virus, and
the mixture was added to microplates coated previously with
1 μg/ml 8H5, and, after incubation for 30 min, the amount of
virus bound was determined by ELISA using another anti-H5N1
mAb (2F2) labelled previously with HRP. Compared with results
obtained concurrently with viruses alone, the presence of fusion
proteins was found to reduce the amount of virus bound to 8H5-
coated plates by 25–85%, whereas HBc alone did not affect virus
binding.
To analyse further the relationship between 8H5 specificity of
peptides and native HA, mouse antisera were raised against HBc-
fusion proteins. Antigenic specificity of the antisera was evaluated
by cross-titration against p239 and different p239-fusion proteins
(Table 4). The results show that each antiserum was reactive
against a p239-fusion protein carrying the homologous peptide
and variously reactive against the other fusion proteins, but was
not reactive against the parental p239. Similarly to Figure 2, 8H5
was reactive with p239-bearing peptides 122, 123, 125 and
129, but not those bearing peptides 124 and 129. Antisera
against fusion proteins carrying peptides 123 or 128 exhibited
broad cross-reactivity against heterologous peptides, and anti-
122 was the least cross-reacting. These findings suggest that
the antisera are reactive against homologous peptides carried
by the respective fusion proteins and variously cross-reacting
against other heterologous peptides. However, the cross-reactivity
patterns of anti-peptide sera did not discriminate between fusion
proteins that are reactive and not reactive with 8H5.
Nevertheless, the antisera were reactive against Sf21 cells
transfected with the HA gene of the YU22 strain of H5N1 virus,
but not the parental cells, whereas antisera raised against HBc
alone was not reactive against either the transfected or the parental
cells (Figure 5). On the other hand, the antisera did not cause
haemagglutination inhibition mediated by H5N1 avian influenza
virus, nor neutralization (results not shown).
DISCUSSION
We have generated 52 broad-spectrum H5-specific mAbs, which
exhibit HI reactivity against all ten major genetic groups of H5N1
avian influenza virus prevalent since 1997, and virtually all of
these antibodies tested also showed broad-spectrum neutralizing
activities against these viruses [15,16]. One of these antibodies
was shown further to protect mice against different groups of the
virus, even when the antibody was administered after the infection
has disseminated to different organs [16]. The sites recognized
by these neutralizing and/or HI antibodies are referred to as
neutralization epitopes or HI epitopes, and, as such, they constitute
potential targets for intervention of a wide variety of H5N1 avian
influenza viruses. The structure of the neutralization or HI sites
is not known. They are operationally defined as those which are
recognized by neutralizing or HI antibodies, and binding of the
latter to the sites would arrest infection or effect HI, presumably
by blocking binding of the virus to its receptors on host cells or
to the red blood cells.
The present study aims to identify peptides that mimic the
neutralization site recognized by one of the broad-spectrum anti-
H5 mAbs, 8H5. This was achieved by repeatedly panning a
combinatorial 12-mer peptide phage display library with this
antibody. The screened phage was tested individually by ELISA to
determine the reactivity of each with 8H5. Three antibodies were
included as controls in these studies; two were broad-spectrum
anti-H5 mAbs, similar to 8H5, and one is specific for HEV,
unrelated to the anti-H5N1 avian influenza virus antibodies. Phage
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Table 3 8H5 reactivity of 12-mer peptides associated with different carriers
Peptides carried by phage particles or particulate forms of p239 or HBc were tested for 8H5 binding by ELISA (see Figures 1 and 2) and that of the peptides carried by the monomeric and dimeric
forms of p239 and HBc was tested by Western blotting (see Figure 3). [+] indicates positive binding results; [−] negative binding results; nd, not detected.
Carrier 8H5 binding with peptides
Type Structure 122 123 124 125 128 129 130,131,133
Phage Particulate [+] [+] [+] [+] [+] [+] [+]
p239 Particulate [+] [+] [−] [+] [−] [+] [−]
Dimeric [+] [+] [−] [+] [−] [−] nd
Monomeric [−] [−] [−] [−] [−] [−] nd
HBc antigen Particulate [+] [+] [+] [+] [+] [+] [−]
Dimeric [−] [−] [−] [+] [−] [−] nd
Monomeric [−] [−] [−] [−] [−] [−] nd
Figure 3 Western blot analysis of p239- and HBc-fusion proteins
Fusion proteins of p239 (top panels) and HBc (bottom panels) described in Figure 2 were subjected to SDS/PAGE (12 % polyacrylamide gel) and Coomassie-stained (left-hand panels), transferred
on to a nitrocellulose membrane, and reacted with 8H5 mAb (right-hand panels). The amounts of samples loaded to the gel was 5–20 μg of E2 and E2-fusion protein and 6–20 μg of HBc and
HBc-fusion protein. Molecular masses are indicated in kDa.
was considered to be specifically reactive with 8H5 when the mean
level of binding with this antibody exceeded at least 3-fold the
values obtained concurrently with all three control antibodies.
Peptides reactive with 8H5 were identified by sequencing the
respective inserts from the phage clones, expressed and purified
as HBc-fusion and HEV structural protein (p239). Antibody
binding to the fusion proteins was determined by ELISA under
non-denaturing conditions, where the fusion proteins occurred in
particulate form, and by Western blotting after fusion proteins
had been resolved mainly into dimeric and monomeric forms by
SDS/PAGE. The relationship between the 8H5-specificity of the
peptides and native H5 molecule was assessed according to
the capacity of the fusion protein to compete with H5N1 virus
for binding with the antibody and that of antisera generated
c© The Authors Journal compilation c© 2009 Biochemical Society
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Table 4 Cross-titration of anti-peptide sera
Anti-peptide sera generated by immunizing mice with HBc-fusion proteins carrying different pep-
tides and 8H5 were tested by ELISA in triplicate against p239 and p239-fusion proteins carrying
these peptides. Binding is shown as mean absorbance values. Note that anti-peptide sera were
reactive against homologous peptides and variously reactive against heterologous peptides, but
not against p239, whereas 8H5 was reactive with p239-fusion proteins bearing four of the
peptides, similarly to Figure 2.
Anti-peptide sera (mean absorbance)
Peptide 122 123 124 125 128 129 8H5
122 1.6 0.337 0.06 0.199 0.361 0.06 1.7
123 0.007 1.0 0.012 0.023 0.695 0.009 2.8
124 0.023 0.134 1.4 0.078 0.308 0.199 0.06
125 0.186 0.971 0.128 1.2 1.844 0.297 2.7
128 0.007 0.421 0.095 0.359 0.9 0.113 0.03
129 0.195 0.965 2.525 1.01 1.902 2.7 0.8
p239 0.0005 0.003 0.008 0.004 0.006 0.007 0.004
Figure 4 Fusion proteins compete with H5N1 virus for 8H5 binding
A 10 μg/ml concentration of HBc carrying different peptides or the parental HBc protein was
mixed with H5N1 avian influenza virus (HK821 and YU22 at 4HA, 6151 at 8HA and 2A at
2HA). The mixtures were added to microtitre plates coated previously with 1 μg/ml 8H5. The
plates were incubated for 30 min and washed, and the amount of viruses bound to 8H5 was
determined using another anti-H5N1 mAb, 2F2–HRP. Experiments were carried out in triplicate
and results are means +− S.D. Mean residual virus bound, [R], was calculated, where R = mean
virus bound (absorbance) in the presence of fusion protein/mean virus bound in the absence of
fusion protein. Mean percentage blocking of virus binding by fusion protein = 100−R.
against the fusion proteins to bind native HA molecule and block
haemagglutination and arrest infection by the virus.
Results show that 69 of 190 randomly tested clones of the
screened phage are 8H5-reactive. DNA sequencing of inserts from
the reactive phage clones identified nine peptides of different
amino acid sequences. It was noted that six peptides which
accounted for 95% (63/69) of all peptides identified share the
same feature that they all have the amino acid residues threonine,
leucine, threonine and leucine preserved in the same positions, 2,
4, 5 and 9, in the respective sequences. The same six peptides,
but not the other three, were reactive with 8H5 when they were
associated with native form of HBc, and four of which were
reactive in association with native form of p239. Western blotting
shows that 8H5 reactivity of three peptides was preserved in
the dimeric form p239 and that of one peptide was preserved
in dimeric form of HBc, but the reactivity of the peptides was
abrogated after the fusion proteins had been dissociated into
their respective monomeric forms. These findings suggest that
8H5 recognizes discontinuous amino acid residues presented by
secondary, or possibly higher, structural orders of the peptides
in spatially favourable positions for binding to occur, and it
is possible that these may include some or all of the amino
acid residues threonine, leucine, threonine and leucine locating
to positions 2, 4, 5 and 9 respectively of the peptides. This
interpretation would be consistent with the findings that each
Figure 5 Reactivity of HBc-fusion protein antisera against HA of H5N1 virus
Sf21 cells expressing HA of YU22 strain of H5N1 virus were reacted with antisera generated
against different HBc-fusion proteins as indicated (shaded) or anti-HBc (not shaded) and
examined by flow cytometry.
of the reactive peptides have distinct amino acid sequences,
recognition of which by 8H5 depends on the type of carrier
molecule and their respective tertiary and higher structural orders,
and that binding did not occur with the monomeric form of the
fusion proteins.
The relationship between 8H5-specificity of the native HA
molecule and the peptides was investigated. The results show that
HBc-fusion proteins bearing the peptides competed with different
strains of H5N1 virus for 8H5 binding and that anti-peptide sera
bind to native HA molecules expressed by Sf21 cells; they did
not inhibit haemagglutination nor neutralize infection (results not
shown) caused by the virus. Saphire et al. [28] and Menendez
et al. [29] recently compared the X-ray crystallography of the
immune complexes consisting of gp120 (glycoprotein 120) of
HIV1 and an antibody produced against the native protein, which
could cross-react with gp120 of HIV2, with that consisting of an
antibody generated against the peptide mimic of the cross-reacting
epitope, which binds with HIV1, but did not cross-react with
HIV2. The authors showed that the native cross-reacting epitope is
not identical with that identified by the antibody generated against
the peptide mimics and suggest that the incomplete mimicry
of the cross-reacting gp120 epitope could account, at least in part,
for the functional deficiency of the anti-peptide. Incomplete
mimicry of functional epitopes, such as the 8H5-neutralization
epitope and the HIV1- and HIV2-cross-reacting epitopes, appears
to be a common difficulty encountered in previous studies,
resulting in functionally defective antibodies raised against the
peptide mimics [30,31]. Nevertheless, our results suggest that
the 8H5-reactive peptides and the native neutralization epitope
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recognized by the antibody might share certain structural features,
to the extent that the antisera produced against these peptides also
specifically bind to the HA molecule. Our findings suggest further
it is possible that the amino acid residues threonine, leucine,
threonine and leucine located at positions 2, 4, 5 and 9 respectively
of all of these reactive peptides might constitute a part of the
neutralization epitope recognized by 8H5.
ACKNOWLEDGEMENTS
We thank Dr Jeng-Hsiung Frank Peng and Dr James Wai-Kuo Shih for helpful comments
and a critical review of this manuscript before submission.
FUNDING
This work was supported by the Science and Technology Foundation of Fujian Province
[grant numbers 2008Y0059 and F2006BAI01B06]; the Key Project of Chinese Ministry
of Education [grant number 108157]; and the Foundation from Ministry of Science and
Technology [grant number 2005DC105006].
REFERENCES
1 Webster, R. G. and Hulse, D. J. (2004) Microbial adaptation and change: avian influenza.
Rev. Sci. Tech. 23, 453–465
2 Reference deleted
3 Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C. and
Katz, J. M. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after
vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97
(H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191, 1210–1215
4 Stephenson, I., Gust, I., Pervikov, Y. and Kieny, M. P. (2006) Development of vaccines
against influenza H5. Lancet Infect. Dis. 6, 458–460
5 Hoffmann, E., Mahmood, K., Chen, Z., Yang, C. F., Spaete, J., Greenberg, H. B., Herlocher,
M. L., Jin, H. and Kemble, G. (2005) Multiple gene segments control the temperature
sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J. Virol. 79, 11014–11021
6 Belshe, R. B., Edwards, K. M., Vesikari, T., Black, S. V., Walker, R. E., Hultquist, M.,
Kemble, G. and Connor, E. M. (2007) Live attenuated versus inactivated influenza vaccine
in infants and young children.
N. Engl. J. Med. 356, 685–696
7 Hoelscher, M. A., Garg, S., Bangari, D. S., Belser, J. A., Lu, X., Stephenson, I., Bright,
R. A., Katz, J. M., Mittal, S. K. and Sambhara, S. (2006) Development of adenoviral-
vector-based pandemic influenza vaccine against antigenically distinct human H5N1
strains in mice. Lancet 367, 475–481
8 Veits, J., Wiesner, D., Fuchs, W., Hoffmann, B., Granzow, H., Starick, E., Mundt, E.,
Schirrmeier, H., Mebatsion, T., Mettenleiter, T. C. and Romer-Oberdorfer, A. (2006)
Newcastle disease virus expressing H5 HA gene protects chickens against Newcastle
disease and avian influenza. Proc. Natl. Acad. Sci. U.S.A. 103, 8197–8202
9 Ge, J., Deng, G., Wen, Z., Tian, G., Wang, Y., Shi, J., Wang, X., Li, Y., Hu, S., Jiang, Y.
et al. (2007) Newcastle disease virus-based live attenuated vaccine completely protects
chickens and mice from lethal challenge of homologous and heterologous H5N1 avian
influenza viruses. J. Virol. 81, 150–158
10 Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M. and Fiers, W. (1999) A
universal influenza A vaccine based on the extracellular domain of the M2 protein.
Nat. Med. 5, 1157–1163
11 Ernst, W. A., Kim, H. J., Tumpey, T. M., Jansen, A. D., Tai, W., Cramer, D. V., Adler-Moore,
J. P. and Fujii, G. (2006) Protection against H1, H5, H6 and H9 influenza A infection with
liposomal matrix 2 epitope vaccines. Vaccine 24, 5158–5168
12 De Filette, M., Ramne, A., Birkett, A., Lycke, N., Lowenadler, B., Min Jou, W., Saelens, X.
and Fiers, W. (2006) The universal influenza vaccine M2e–HBc administered intranasally
in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24,
544–551
13 Kendal, A. P., Pereira, M. S. and Skehel, J. J. (1982) Hemagglutination inhibition. In
Concepts and Procedures for Laboratory-Based Influenza Surveillance, (Kendal, A. P.,
Pereira, M. S. and Skehel, J. J. eds), pp. B17–B35, Centers for Disease Control and
Prevention and Pan-American Health Organization, Atlanta
14 World Health Organization Global Influenza Program Surveillance Network (2005)
Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515–1521
15 Wu, W. L., Chen, Y., Wang, P., Song, W., Lau, S. Y., Rayner, J. M., Smith, G. J., Webster,
R. G., Peiris, J. S., Lin, T. et al. (2008) Antigenic profile of avian H5N1 viruses in Asia
from 2002 to 2007. J. Virol. 82, 1798–1807
16 Chen, Y., Qin, K., Wu, W. L., Li, G., Zhang, J., Du, H., Ng, M. H., Shih, J. W.-K.,
Guan, Y., Chen, H. and Xia, N. (2008) Broad cross protection against H5N1 avian
influenza infection using monoclonal antibodies mapping to conserved viral epitopes.
J. Infect. Dis. 199, 49–58
17 Purcell, A. W., McCluskey, J. and Rossjohn, J. (2007) More than one reason to rethink the
use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404–414
18 Boss, C. N., Grunebach, F., Brauer, K., Hantschel, M., Mirakaj, V., Weinschenk, T.,
Stevanovic, S., Rammensee, H. G. and Brossart, P. (2007) Identification and
characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor
antigen. Clin. Cancer Res. 13, 3347–3355
19 Chen, X., Scala, G., Quinto, I., Liu, W., Chun, T. W., Justement, J. S., Cohen, O. J.,
vanCott, T. C., Iwanicki, M., Lewis, M. G. et al. (2001) Protection of rhesus macaques
against disease progression from pathogenic SHIV-89.6PD by vaccination with
phage-displayed HIV-1 epitopes. Nat. Med. 7, 1225–1231
20 Khurana, S., Needham, J., Mathieson, B., Rodriguez-Chavez, I. R., Catanzaro, A. T., Bailer,
R. T., Kim, J., Polonis, V., Cooper, D. A., Guerin, J. et al. (2006) Human immunodeficiency
virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the
face of vaccine-generated antibodies. J. Virol. 80, 2092–2099
21 Steward, M. W. (2001) The development of a mimotope-based synthetic peptide vaccine
against respiratory syncytial virus. Biologicals 29, 215–219
22 Torresi, J., Stock, O. M., Fischer, A. E., Grollo, L., Drummer, H., Boo, I., Zeng, W.,
Earnest-Silveira, L. and Jackson, D. C. (2007) A self-adjuvanting multiepitope
immunogen that induces a broadly cross-reactive antibody to hepatitis C virus.
Hepatology 45, 911–920
23 Zhang, J., Gu, Y., Ge, S. X., Li, S. W., He, Z. Q., Huang, G. Y., Zhuang, H., Ng, M. H. and
Xia, N. S. (2005) Analysis of hepatitis E virus neutralization sites using monoclonal
antibodies directed against a virus capsid protein. Vaccine 23, 2881–2892
24 Li, S. W., Zhang, J., He, Z. Q., Gu, Y., Liu, R. S., Lin, J., Chen, Y. X., Ng, M. H. and Xia,
N. S. (2005) Mutational analysis of essential interactions involved in the assembly of
hepatitis E virus capsid. J. Biol. Chem. 280, 3400–3406
25 Borisova, G., Borschukova Wanst, O., Mezule, G., Skrastina, D., Petrovskis, I., Dislers, A.,
Pumpens, P. and Grens, E. (1996) Spatial structure and insertion capacity of
immunodominant region of hepatitis B core antigen. Intervirology 39, 16–22
26 Milich, D. R., Peterson, D. L., Zheng, J., Hughes, J. L., Wirtz, R. and Schodel, F. (1995)
The hepatitis nucleocapsid as a vaccine carrier moiety. Ann. N.Y. Acad. Sci. 754, 187–201
27 World Health Organization (2002) WHO Manual on Animal Influenza Diagnosis and
Surveillance, 2nd edn, World Health Organization. Geneva, Switzerland, http://www.who.
int/csr/resources/publications/influenza/en/whocdscsrncs20025rev.pdf
28 Saphire, E. O., Montero, M., Menendez, A., van Houten, N. E., Irving, M. B.,
Pantophlet, R., Zwick, M. B., Parren, P. W., Burton, D. R., Scott, J. K. and Wilson, I. A.
(2007) Structure of a high-affinity “mimotope” peptide bound to HIV-1-neutralizing
antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J. Mol. Biol.
369, 696–709
29 Menendez, A., Calarese, D. A., Stanfield, R. L., Chow, K. C., Scanlan, C. N., Kunert, R.,
Katinger, H., Burton, D. R., Wilson, I. A. and Scott, J. K. (2008) A peptide inhibitor of
HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate
epitope on gp120. FASEB J. 22, 1380–1392
30 Dharmasena, M. N., Jewell, D. A. and Taylor, R. K. (2007) Development of peptide mimics
of a protective epitope of Vibrio cholerae Ogawa O-antigen and investigation of the
structural basis of peptide mimicry. J. Biol. Chem. 282, 33805–33816
31 Joyce, J. G., Krauss, I. J., Song, H. C., Opalka, D. W., Grimm, K. M., Nahas, D. D., Esser,
M. T., Hrin, R., Feng, M., Dudkin, V. Y. et al. (2008) An oligosaccharide-based HIV-1
2G12 mimotope vaccine induces carbohydrate- specific antibodies that fail to neutralize
HIV-1 virions. Proc. Natl. Acad. Sci. U.S.A. 105, 15684–15689
Received 10 January 2008/15 October 2008; accepted 30 October 2008
Published as BJ Immediate Publication 30 October 2008, doi:10.1042/BJ20080083
c© The Authors Journal compilation c© 2009 Biochemical Society
